Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib

Treatment with CDK 4/6 inhibitors is well tolerated and associated with a low risk of treatment-related deaths. There is an increased AR of grade 3/4 neutropenia but a low AR of associated infections.